{"filing":{"accession_number":"0001104659-26-105688","cik":"0001888886","ticker":"GPCR","company_name":"Structure Therapeutics Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"tm2624945d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_8k.htm"},"events":[{"id":31825,"run_id":29224,"accession_number":"0001104659-26-105688","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Structure Therapeutics announced positive topline clinical trial results for two lead product candidates: ACCG-2671 (Phase 1/2a SAD results showing ~6-day half-life, 3.3% body weight loss, no serious adverse events) and aleniglipron (72-week ACCESS OLE results showing up to 16.2% body weight loss with improved tolerability). These material clinical milestones represent significant operational and strategic progress for the clinical-stage biopharmaceutical company's pipeline.","company_name":"Structure Therapeutics Inc.","ticker":"GPCR","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34831,"accession_number":"0001104659-26-105688","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Structure Therapeutics announced positive topline clinical trial results for two lead product candidates: ACCG-2671 (Phase 1/2a SAD results showing ~6-day half-life, 3.3% body weight loss, no serious adverse events) and aleniglipron (72-week ACCESS OLE results showing up to 16.2% body weight loss with improved tolerability). While this is clinical progress rather than a traditional earnings release or financial result, the disclosure of material clinical milestones for lead programs in a clinical-stage biopharmaceutical company represents a significant operational and strategic event that would affect a reasonable investor's assessment of the company's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:10:42.615522+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34832,"accession_number":"0001104659-26-105688","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Structure Therapeutics disclosed positive Phase 1/2a clinical trial results for two lead product candidates: ACCG-2671 (amylin receptor agonist) showing favorable safety, tolerability, and early pharmacodynamic activity including 3.3% body weight loss; and aleniglipron (GLP-1 receptor agonist) demonstrating up to 16.2% weight loss at 72 weeks with improved tolerability. These are material clinical milestones for a clinical-stage biopharmaceutical company that would affect investor assessment of pipeline progress and commercial potential, but do not fit the specific earnings_release category (which typically applies to financial results) or other named event types. The disclosure centers on operational/clinical development progress rather than financial results, M\u0026A, governance, or other specific material event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:10:42.615522+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34831,"accession_number":"0001104659-26-105688","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Structure Therapeutics announced positive topline clinical trial results for two lead product candidates: ACCG-2671 (Phase 1/2a SAD results showing ~6-day half-life, 3.3% body weight loss, no serious adverse events) and aleniglipron (72-week ACCESS OLE results showing up to 16.2% body weight loss with improved tolerability). While this is clinical progress rather than a traditional earnings release or financial result, the disclosure of material clinical milestones for lead programs in a clinical-stage biopharmaceutical company represents a significant operational and strategic event that would affect a reasonable investor's assessment of the company's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:10:42.615522+00:00","company_name":"Structure Therapeutics Inc.","ticker":"GPCR","filing_date":"2026-09-08"},{"id":34832,"accession_number":"0001104659-26-105688","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Structure Therapeutics disclosed positive Phase 1/2a clinical trial results for two lead product candidates: ACCG-2671 (amylin receptor agonist) showing favorable safety, tolerability, and early pharmacodynamic activity including 3.3% body weight loss; and aleniglipron (GLP-1 receptor agonist) demonstrating up to 16.2% weight loss at 72 weeks with improved tolerability. These are material clinical milestones for a clinical-stage biopharmaceutical company that would affect investor assessment of pipeline progress and commercial potential, but do not fit the specific earnings_release category (which typically applies to financial results) or other named event types. The disclosure centers on operational/clinical development progress rather than financial results, M\u0026A, governance, or other specific material event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:10:42.615522+00:00","company_name":"Structure Therapeutics Inc.","ticker":"GPCR","filing_date":"2026-09-08"}]}